X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs WOCKHARDT LTD. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS WOCKHARDT LTD. IPCA LABS/
WOCKHARDT LTD.
 
P/E (TTM) x 30.4 -24.4 - View Chart
P/BV x 3.6 2.5 146.2% View Chart
Dividend Yield % 0.1 0.0 8,324.4%  

Financials

 IPCA LABS   WOCKHARDT LTD.
EQUITY SHARE DATA
    IPCA LABS
Mar-18
WOCKHARDT LTD.
Mar-18
IPCA LABS/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs6951,012 68.7%   
Low Rs400532 75.3%   
Sales per share (Unadj.) Rs260.2355.9 73.1%  
Earnings per share (Unadj.) Rs19.0-60.3 -31.5%  
Cash flow per share (Unadj.) Rs33.1-46.8 -70.7%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.20 14,090.7%  
Book value per share (Unadj.) Rs213.0257.8 82.6%  
Shares outstanding (eoy) m126.20110.63 114.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.2 97.1%   
Avg P/E ratio x28.9-12.8 -225.5%  
P/CF ratio (eoy) x16.6-16.5 -100.4%  
Price / Book Value ratio x2.63.0 85.9%  
Dividend payout %5.30 -31,772.7%   
Avg Mkt Cap Rs m69,12085,379 81.0%   
No. of employees `00013.36.3 211.9%   
Total wages/salary Rs m7,3599,371 78.5%   
Avg. sales/employee Rs Th2,477.46,295.0 39.4%   
Avg. wages/employee Rs Th555.21,498.3 37.1%   
Avg. net profit/employee Rs Th180.6-1,066.3 -16.9%   
INCOME DATA
Net Sales Rs m32,83639,369 83.4%  
Other income Rs m4181,202 34.8%   
Total revenues Rs m33,25440,571 82.0%   
Gross profit Rs m4,50518 24,616.4%  
Depreciation Rs m1,7771,495 118.9%   
Interest Rs m2402,555 9.4%   
Profit before tax Rs m2,905-2,830 -102.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m511257 198.9%   
Profit after tax Rs m2,394-6,669 -35.9%  
Gross profit margin %13.70 29,514.3%  
Effective tax rate %17.6-9.1 -193.7%   
Net profit margin %7.3-16.9 -43.0%  
BALANCE SHEET DATA
Current assets Rs m19,45533,796 57.6%   
Current liabilities Rs m10,07626,917 37.4%   
Net working cap to sales %28.617.5 163.5%  
Current ratio x1.91.3 153.8%  
Inventory Days Days9879 123.4%  
Debtors Days Days6789 75.0%  
Net fixed assets Rs m20,26039,664 51.1%   
Share capital Rs m252553 45.6%   
"Free" reserves Rs m26,63327,968 95.2%   
Net worth Rs m26,88628,522 94.3%   
Long term debt Rs m2,34021,731 10.8%   
Total assets Rs m41,17381,620 50.4%  
Interest coverage x13.1-0.1 -12,179.6%   
Debt to equity ratio x0.10.8 11.4%  
Sales to assets ratio x0.80.5 165.3%   
Return on assets %6.4-5.0 -127.0%  
Return on equity %8.9-23.4 -38.1%  
Return on capital %10.8-7.7 -140.2%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6429,807 159.5%   
Fx outflow Rs m4,8841,789 273.0%   
Net fx Rs m10,7598,019 134.2%   
CASH FLOW
From Operations Rs m3,411684 498.4%  
From Investments Rs m-1,3546,302 -21.5%  
From Financial Activity Rs m-1,304-7,695 16.9%  
Net Cashflow Rs m753-664 -113.4%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 2.3 495.7%  
FIIs % 25.3 7.7 328.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 67,757 54.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 18, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS